Copaxone Patent Stuck in Supreme Court Stalemate
the Neurology Advisor take:
The battle over patents for a popular multiple sclerosis drug are heating up as the U.S. Supreme Court decides whether to overturn a ruling by the U.S. Court of Appeals, which ruled in favor of the generic drug companies that are creating cheaper forms of Teva Pharmaceutical’s Copaxone.
So far, several justices have expressed concern over challenging the appeals system, in which the Appeals Court holds much weight over the findings of lower courts.
In a previous ruling, a lower court had ruled in favor of Teva. However, that ruling was overturned by the Court of Appeals in favor of Sandoz Inc. and Momenta Pharmaceuticals, who are developing a generic drug. Mylan Inc. and Natco Pharma are also developing generic versions of the drug.
The Supreme Court justices are primarily concerned by the Appeals court decision, since the lower federal court actually heard arguments and examined evidence first-hand before passing down a decision in favor of Teva.
While the Supreme Court decides its course of action, Teva is extremely vulnerable; since the Appeals court deemed Teva’s patent as invalid, Copaxone is not currently patent-protected, and Mylan said it could launch its drug before the end of 2014.
In the meantime, Teva is switching patients currently on Copaxone to a new patent-protected formulation of medication.
Supreme Court Divided Over Patent for Teva's MS Drug
Next Article in Multiple Sclerosis
Neurology Advisor Articles
- Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Gender Differences in the Epidemiology of Migraine
- Changes in Glucose Regulation in Parkinson Disease
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Locally Asymptomatic Ischemic Stroke May Present as Migraine Aura
- Associations Identified Between Stroke Severity, Recovery of Visuospatial Neglect
- Action Tremor May Have Central Origin in Motor Neuron Disease
- Characteristics Affecting Health-Related Quality of Life in RRMS, Progressive MS
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd